Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]

What It Covers

Zach Reitano, CEO of Ro, argues that US healthcare spending should rise well above 18% of GDP as AI and GLP-1 drugs reshape the system. He covers Ro's growth from $250M to $3B run rate, the structural flaw of patients not being customers, and why removing insurance middlemen drives prices down while improving outcomes.

Key Questions Answered

• •Patient-as-customer framework: The single root cause of US healthcare dysfunction is that patients pay for care but are not the actual customer—insurers and employers control spending decisions. Where cash-pay markets exist, such as LASIK, cosmetic surgery, and direct GLP-1 prescriptions, prices fall and quality rises. Ro's model aggregates patient spend to bend the system toward patient priorities on cost, quality, and convenience.
• •PBM elimination math: When GLP-1 manufacturers sold direct-to-consumer and bypassed pharmacy benefit managers, branded drug prices dropped from $1,300 to $149—an 89% reduction—while manufacturer gross profit increased. This pattern mirrors Jevons Paradox: lower cost per unit expands total market size. Founders building in healthcare should identify which intermediaries capture margin without adding patient value and route around them entirely.
• •Sequential over parallel building: Ro grew 10x while reducing headcount from 600 to 400 by abandoning parallel workstreams. Building features sequentially—completing one fully before starting the next—compounds like interest, reaching year-30 of a compound curve rather than stalling at year-10. Reitano ran a daily 8:50am leadership alignment meeting for two straight years to maintain 24-hour decision cycles and eliminate context-switching.
• •Strong attract, strong repel culture: Ro's refounding in 2022 centered on explicitly articulating a dual culture of extreme performance and genuine care—both at maximum intensity simultaneously. After 20% of staff departed voluntarily post-articulation, the remaining team 10x'd revenue. The framework: treat culture like a restaurant menu—eliminate bugs (execution failures), double down on features (defining characteristics), and make the menu public so candidates self-select before joining.
• •GLP-1 adoption trajectory: Roughly 75% of the US population is clinically eligible for GLP-1s based on overweight or obesity criteria, and only 10-12% of Americans are metabolically healthy. Reitano projects 50%+ of Americans will be on some form of GLP-1 within 10-15 years, comparing the trajectory to statins, which reached 40-50 million users. New oral PCSK9 inhibitors and expanded GLP-1 indications covering sleep apnea, kidney disease, and neurodegeneration accelerate this timeline.
• •Jobs-over-lives fallacy in healthcare AI: Autonomous vehicles have demonstrated 10-20x safety improvements over human drivers, yet regulatory resistance persists partly due to organ donation concerns and job displacement fears. Reitano applies this directly to healthcare AI: tools must prove substantial superiority over the status quo, but the status quo deserves no protection simply because it exists. Prioritizing inputs over outcomes in healthcare carries a measurable body count that future generations will assign to specific decision-makers.